T cell receptor alpha variable 32 (TRAV32)

T cell receptor alpha variable 32 (TRAV32) is a variable (V) gene segment within the TCR alpha (TRA) locus on human chromosome 14[3][4]. The TCR is expressed on the surface of T cells and is responsible for recognizing antigens presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells[1]. The diversity of TCRs arises from somatic recombination of multiple V (like TRAV32), J, and C gene segments, enabling the adaptive immune system to recognize an immense variety of pathogens and abnormal cells[3][4]. TRAV32 contributes to the antigen-binding domain of the TCR alpha chain, influencing the specificity of T cell responses. Abnormalities in TCR gene usage or structure, including skewed use of specific segments such as TRAV32, have been implicated in immune deficiency, autoimmunity, infections, and cancer[1][2][3]. TRAV32 itself is not directly druggable, but the TCR complex (in which TRAV32 can participate) is the focus of emerging immunotherapeutic strategies, such as engineered TCR T cells, TCR mimic antibodies, and immune checkpoint inhibitors[2]. If further specificity is needed about the genetic or structural details of TRAV32, refer to the IMGT (International ImMunoGeneTics information system) database for the full gene sequence and additional annotation[3][4].

Other names

TCRAV32S1TRAV32

Activation or redirection of T cells to target specific cells (as in adoptive T cell therapies, TCR-mimic antibodies); Blocking or enhancing TCR signaling (e.g., checkpoint inhibitors modulate downstream TCR signaling to restore activity in exhausted T cells).